Literature DB >> 6165018

Does OKT3 monoclonal antibody react with an antigen-recognition structure on human T cells?

T W Chang, P C Kung, S P Gingras, G Goldstein.   

Abstract

OKT3 monoclonal antibody to human T cells inhibits the target cell lysis mediated by allogeneic cytotoxic T cells and the generation of these effector cells in mixed lymphocyte culture. This marked inhibition of cell-mediated lysis is not found with other monoclonal antibodies also reactive with cell surface antigens of human T cells (OKT1, OKT4, OKT5, OKT6, OKT8, and OKT11). OKT3 antibody is mitogenic and this effect appears to require receptor activation in that it occurs at low concentrations (10(-12) M range) of OKT3 antibody, requires intact OKT3 IgG, and is inhibited by a factor(s) in human plasma. By contrast, the inhibition of allogeneic cell-mediated lysis by OKT3 antibody appears to be due to steric hindrance in that it requires higher concentrations of OKT3 antibody (10(-8) M range), Fab fragments retain approximately 10% activity, and inhibition is demonstrable in the presence of human plasma. These findings are consistent with the suggestion that OKT3 antibody reacts with the human T-cell antigen-recognition structure.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6165018      PMCID: PMC319223          DOI: 10.1073/pnas.78.3.1805

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  26 in total

1.  Production of monoclonal antibodies reacting with peripheral blood mononuclear cell surface differentiation antigens.

Authors:  G S Eisenbarth; B F Haynes; J A Schroer; A S Fauci
Journal:  J Immunol       Date:  1980-03       Impact factor: 5.422

Review 2.  Expression and function of idiotypes of lymphocytes.

Authors:  K Eichmann
Journal:  Adv Immunol       Date:  1978       Impact factor: 3.543

3.  OKT3: a monoclonal anti-human T lymphocyte antibody with potent mitogenic properties.

Authors:  J P Van Wauwe; J R De Mey; J G Goossens
Journal:  J Immunol       Date:  1980-06       Impact factor: 5.422

4.  Strategies for generating monoclonal antibodies defining human t-lymphocyte differentiation antigens.

Authors:  P C Kung; M A Talle; M E DeMaria; M S Butler; J Lifter; G Goldstein
Journal:  Transplant Proc       Date:  1980-09       Impact factor: 1.066

5.  Effects of N alpha-tosyl-L-lysyl-chloromethylketone on the activity of cytotoxic T lymphocytes.

Authors:  T W Chang; H N Eisen
Journal:  J Immunol       Date:  1980-03       Impact factor: 5.422

6.  Functional and developmental compartments of human T lymphocytes.

Authors:  P C Kung; G Goldstein
Journal:  Vox Sang       Date:  1980-09       Impact factor: 2.144

7.  Discrete stages of human intrathymic differentiation: analysis of normal thymocytes and leukemic lymphoblasts of T-cell lineage.

Authors:  E L Reinherz; P C Kung; G Goldstein; R H Levey; S F Schlossman
Journal:  Proc Natl Acad Sci U S A       Date:  1980-03       Impact factor: 11.205

8.  Mouse alloantibodies capable of blocking cytotoxic T cell function. II. Further study on the relationship between the blocking antibodies and the products of the Lyt-2 locus.

Authors:  N Shinohara; U Hämmerling; D H Sachs
Journal:  Eur J Immunol       Date:  1980-08       Impact factor: 5.532

9.  Effect of antilyphocyte-globulin potency on survival of cadaver renal transplants. Prospective randomised double-blind trial.

Authors:  F Thomas; G Mendez-Picon; J Thomas; K Peace; R Flora; H M Lee
Journal:  Lancet       Date:  1977-10-01       Impact factor: 79.321

10.  Antigen- and receptor-driven regulatory mechanisms. I. Induction of suppressor T cells with anti-idiotypic antibodies.

Authors:  M S Sy; B A Bach; Y Dohi; A Nisonoff; B Benacerraf; M I Greene
Journal:  J Exp Med       Date:  1979-11-01       Impact factor: 14.307

View more
  62 in total

Review 1.  The birth pangs of monoclonal antibody therapeutics: the failure and legacy of Centoxin.

Authors:  Lara Marks
Journal:  MAbs       Date:  2012-04-26       Impact factor: 5.857

2.  Basis for defective responses of rheumatoid arthritis synovial fluid lymphocytes to anti-CD3 (T3) antibodies.

Authors:  M Lotz; C D Tsoukas; C A Robinson; C A Dinarello; D A Carson; J H Vaughan
Journal:  J Clin Invest       Date:  1986-09       Impact factor: 14.808

Review 3.  The role of OKT3 in clinical transplantation.

Authors:  D J Norman; M R Leone
Journal:  Pediatr Nephrol       Date:  1991-01       Impact factor: 3.714

Review 4.  The human T-cell receptor.

Authors:  O Acuto; M Fabbi; A Bensussan; C Milanese; T J Campen; H D Royer; E L Reinherz
Journal:  J Clin Immunol       Date:  1985-05       Impact factor: 8.317

5.  The T11 glycoprotein is functionally linked to a calcium channel in precursor and mature T-lineage cells.

Authors:  A Alcover; M J Weiss; J F Daley; E L Reinherz
Journal:  Proc Natl Acad Sci U S A       Date:  1986-04       Impact factor: 11.205

6.  In vitro OKT3-induced mitogenesis in selenium-deficient patients on a diet for phenylketonuria.

Authors:  R J Collins; P J Boyle; A E Clague; A E Barr; S C Latham
Journal:  Biol Trace Elem Res       Date:  1991-09       Impact factor: 3.738

7.  Role of monocytes in anti-CD3-induced T-cell DNA synthesis: effect of chloroquine and monensin on anti-CD3-induced human T-cell activation.

Authors:  B Vayuvegula; K Ohira; S Gollapudi; S Gupta
Journal:  J Clin Immunol       Date:  1990-09       Impact factor: 8.317

8.  Mitogen-induced genes are subject to multiple pathways of regulation in the initial stages of T-cell activation.

Authors:  S G Irving; C H June; P F Zipfel; U Siebenlist; K Kelly
Journal:  Mol Cell Biol       Date:  1989-03       Impact factor: 4.272

9.  Polymorphism for RhT3, a CD3-like cell surface antigen, expressed on rhesus monkey T lymphocytes.

Authors:  F J Nooij; W van Vreeswijk; J Coolen
Journal:  Immunology       Date:  1986-12       Impact factor: 7.397

10.  Role of T3 surface molecules in human T-cell activation: T3-dependent activation results in an increase in cytoplasmic free calcium.

Authors:  A Weiss; J Imboden; D Shoback; J Stobo
Journal:  Proc Natl Acad Sci U S A       Date:  1984-07       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.